← All trials
NCT01829698
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2009
- Primary completion
- Jan 1, 2013
- Completion date
- Feb 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 199
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Beijing Trendful Kangjian Medical Information Consulting Limited CompanyLead sponsor
- Capital Medical UniversityOverall official - principal investigator
- Capital Medical UniversityStudy director
- Sun Yat-Sen UniversityStudy director
- NO.6 People's Hospital of HangzhouStudy director
- Peking UniversityStudy director
- Fudan UniversityStudy director
- Kunming Medical UniversityStudy director
- Sichuan UniversityStudy director
- Southern Medical UniversityStudy director
- Zhejiang UniversityStudy director
- Second Military Medical UniversityStudy director
- Jiao Tong UniversityStudy director
- People's Liberation Army of ChinaStudy director
- Huazhong University of Science and TechnologyStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.